JP2021512876A5 - - Google Patents

Info

Publication number
JP2021512876A5
JP2021512876A5 JP2020542141A JP2020542141A JP2021512876A5 JP 2021512876 A5 JP2021512876 A5 JP 2021512876A5 JP 2020542141 A JP2020542141 A JP 2020542141A JP 2020542141 A JP2020542141 A JP 2020542141A JP 2021512876 A5 JP2021512876 A5 JP 2021512876A5
Authority
JP
Japan
Prior art keywords
acid
formula
lipoic
furoic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512876A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/050901 external-priority patent/WO2019150341A1/en
Publication of JP2021512876A publication Critical patent/JP2021512876A/ja
Publication of JP2021512876A5 publication Critical patent/JP2021512876A5/ja
Pending legal-status Critical Current

Links

JP2020542141A 2018-02-05 2019-02-05 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 Pending JP2021512876A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841004306 2018-02-05
IN201841004306 2018-02-05
IN201841008091 2018-03-05
IN201841008091 2018-03-05
PCT/IB2019/050901 WO2019150341A1 (en) 2018-02-05 2019-02-05 Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof

Publications (2)

Publication Number Publication Date
JP2021512876A JP2021512876A (ja) 2021-05-20
JP2021512876A5 true JP2021512876A5 (enExample) 2022-02-02

Family

ID=67480013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542141A Pending JP2021512876A (ja) 2018-02-05 2019-02-05 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用

Country Status (13)

Country Link
US (2) US20200375961A1 (enExample)
EP (1) EP3749303A4 (enExample)
JP (1) JP2021512876A (enExample)
KR (1) KR20200118128A (enExample)
AU (1) AU2019214557A1 (enExample)
BR (1) BR112020015436A2 (enExample)
CA (1) CA3089894A1 (enExample)
IL (1) IL276350A (enExample)
MX (1) MX2020008173A (enExample)
RU (1) RU2020122659A (enExample)
SG (1) SG11202006492SA (enExample)
WO (1) WO2019150341A1 (enExample)
ZA (1) ZA202004058B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386467B (es) * 2016-10-04 2025-03-18 Cellix Bio Private Ltd Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
JP7670945B2 (ja) 2018-10-26 2025-05-01 オーパス・ジェネティクス・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
MX2022014413A (es) * 2020-05-26 2022-12-07 Cellix Bio Private Ltd Formulaciones farmaceuticas de pilocarpina r-(+)-lipoato.
WO2022080529A1 (ko) * 2020-10-15 2022-04-21 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
WO2023052974A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Ocular compositions and methods for the treatment of ophthalmic diseases and disorders
CN116459251B (zh) * 2022-01-18 2024-12-13 苏州普乐康医药科技有限公司 一种含西维美林的眼用制剂及其制备方法和应用
EP4469047A4 (en) * 2022-01-25 2026-03-04 Biotheravision Inc AQUEOUS COMPOSITIONS OF CEVIMELINE AND METHODS OF USE
US20250154135A1 (en) * 2022-01-29 2025-05-15 Nanjing Gritpharma Co., Ltd. M-choline receptor agonist compound, preparation method therefor and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608073A (en) * 1968-07-16 1971-09-21 Barnes Hind Pharm Inc Emulsion of pilocarpine for ophthalmic use
AU2005245240B2 (en) * 2004-05-20 2010-04-29 Scimar Ltd. Use of drug combinations for treating insulin resistance
US20110150974A1 (en) * 2004-08-06 2011-06-23 Daiichi Pharmaceutical Co., Ltd. Agent For Oral Mucosal Administration
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
CA2635603C (en) * 2005-11-30 2016-01-19 Endo Pharmaceuticals Inc. Treatment of xerostomia
UA86441C2 (ru) * 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
US20090263467A1 (en) * 2008-04-21 2009-10-22 Hemant Narahar Joshi Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments
WO2010147962A1 (en) * 2009-06-15 2010-12-23 Encore Health, Llc Choline esters
HRP20140020T1 (hr) * 2009-11-12 2014-02-14 Acacia Pharma Limited Uporaba betanekola za lijeäśenje kserostomije
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
US20140105976A1 (en) * 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9427144B2 (en) * 2014-01-03 2016-08-30 Ophthalmx Llc Methods and systems for detecting ophthalmic disease
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
MX386467B (es) * 2016-10-04 2025-03-18 Cellix Bio Private Ltd Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
SG11202004019SA (en) * 2017-11-17 2020-05-28 Cellix Bio Private Ltd Compositions and methods for the treatment of eye disorders
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用

Similar Documents

Publication Publication Date Title
JP2021512876A5 (enExample)
RU2020122659A (ru) Комбинация антимускаринового или антихолинергического средства и липоевой кислоты и ее применения
JP2004526745A5 (enExample)
AU2012338362B2 (en) Tricyclic compounds, compositions comprising them and uses thereof
DK3157936T3 (en) MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
JP7524411B2 (ja) 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
JP7130818B2 (ja) 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
JP2016534063A5 (enExample)
AU2014209387A1 (en) Toxic aldehyde related diseases and treatment
BR112013020424A2 (pt) Nitrocatecol substituído, utilizações do mesmo, combinação e composição que o compreendem
BR112019011640B1 (pt) Compostos conjugados de d-metilfenidato, composições que compreendem os mesmos e kit farmacêutico que compreende as ditas composições
CN103228618B (zh) 新化合物及其医药用途
RU2019113465A (ru) Композиции и способы лечения ксеростомии
JP2022191331A (ja) 炎症及び疼痛の治療のための組成物及び方法
JP2021534160A5 (enExample)
CN112384214A (zh) 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑
WO2016020919A1 (en) Compositions comprising tricyclic compounds, and uses thereof
US20170319519A1 (en) Combination for the treatment of conditions involving muscular pain
JP2023517919A5 (enExample)
JP2016537431A5 (enExample)
ES2272383T3 (es) Uso de un agente que mejora la funcion astrocitica para el tratamiento de la enfermedad de parkison.
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
JP2005523269A5 (enExample)
JP2023518640A5 (enExample)
JP2023501967A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス